About the Authors

Åsa Nääv

Contributed equally to this work with: Åsa Nääv, Lena Erlandsson

asa.naav@med.lu.se

Affiliation Obstetrics and Gynecology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Lena Erlandsson

Contributed equally to this work with: Åsa Nääv, Lena Erlandsson

Affiliation Obstetrics and Gynecology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Josefin Axelsson

Affiliation Nephrology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Irene Larsson

Affiliation Obstetrics and Gynecology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Martin Johansson

Affiliation Clinical Pathology, Department of Laboratory Medicine, Lund University, Malmö, Sweden

Lena Wester-Rosenlöf

Affiliation Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Matthias Mörgelin

Affiliation Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Vera Casslén

Affiliation Obstetrics and Gynecology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Magnus Gram

Affiliation Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Bo Åkerström

Affiliation Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Stefan R. Hansson

Affiliation Obstetrics and Gynecology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Competing Interests

The authors of this manuscript have read the journal's policy and have the following competing interests: Stefan R Hansson, Bo Åkerström and Magnus Gram hold patents for the diagnosis and treatment of preeclampsia. They are also co-founders of the companies Preelumina Diagnostics AB and A1M Pharma AB (www.a1m.se). The following patents have been filed: 1) A new diagnostic marker and treatment for preeclampsia. First filed January 2007 and PCT filed February 2008 (PCT/EP2008001051) by Bo Åkerström and Stefan Hansson. 2) HbF and A1M as early stage markers for preeclampsia. Appl. No 100323 P14074, filing date March 2010 by Stefan Hansson, Magnus G Olsson and Bo Åkerström. 3) Medical use of the radical scavenger and antioxidantn alpha 1-microglobulin. First filed July 2008 and PCT filed July 2009 (PCT/EP2009/005217-E3-11) by Bo Åkerström, Stefan Hansson, Magnus G Olsson and Martin Olsson. The authors hereby confirm that nothing they have declared alters their adherence to all PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: ÅN LE SH BÅ MG IL LWR JA. Performed the experiments: ÅN LE IL LWR VC JA. Analyzed the data: ÅN LE JA IL MJ MM. Contributed reagents/materials/analysis tools: VC LWR MG BÅ. Wrote the paper: ÅN LE SH. Revised the manuscript: ÅN LE JA IL MJ MM LWR VC MG BÅ SH. Final approval: ÅN LE JA IL MJ MM LWR VC MG BÅ SH.